高效液相色谱法测定微量耳血中头孢他定的浓度

本文介绍采取微量耳血以高效液相色谱法测定头孢他定（Ｃｅｆｔａｚｉｄｉｍｅ）的血药浓度。血样经６％高氯酸沉淀蛋白，流动相为含２５％甲醇的０．０５ｍｏｌ／Ｌ醋酸铵溶液，以冰醋酸调节ｐＨ值至４～５，检测波长为２５４ｎｍ，内标物为头孢唑啉（Ｃｅｆａｚｏｌｉｎ）。经对家兔采取微量耳血测定其血药浓度，可知头孢他定为二室模型，Ｔ＿１／２α为０．１８±０．０５ｈ，Ｔ＿１／２β为１．７５±０．０７ｈ。并对３名住院病人静脉注射１ｇ头孢他定后定时分别取微量耳血进行分析，所得结果与文献基本一致。本文方法简便、快速，结果令人满意。     

2001～2003年上海地区淋病奈瑟菌对抗生素的敏感性测定及质粒分析

目的了解上海地区2001～2003年淋病奈瑟菌(NG)对抗生素的敏感性情况及变化趋势。方法采用琼脂稀释法测定青霉素、头孢曲松、大观霉素、环丙沙星、四环素对742株NG的最小抑菌浓度(MIC)。用纸片酸度法检测β内酰胺酶菌株。用碱裂解方法抽提质粒。结果742株NG检出产青霉素酶菌(PPNG)342株(46.09%);质粒介导高度耐四环素(TRNG)166株(22.37%);耐环丙沙星718株(96.77%);耐大观霉素1株;未发现对头孢曲松耐药菌株;超过20%的菌株同时对青霉素、四环素和环丙沙星耐药;对35株菌株作了质粒分型,含耐药质粒检出率97%,分别带有5.4和7.4kb耐药性质粒。结论淋球菌对青霉素、四环素和环丙沙星3种药物分别有较高比例的耐药率。上海地区治疗淋病应首选大观霉素和头孢曲松。     

氯胺酮对荷包牡丹碱诱导PC12细胞内Ca2+浓度波动方式的影响

目的研究氯胺酮对荷包牡丹碱诱导PCI2细胞内Ca^2＋浓度波动方式的影响。方法使用含25ng／LNGF的DMED培养基在多聚赖氨酸包被的培养皿中培养PCl2细胞；与终浓度10gmol／L的Ca^2＋指示剂Fluo-3 AM ester共孵育30min洗涤后，加入终浓度50gmol／L荷包牡丹碱；在激光共聚焦显微镜选定多个细胞分别测定荧光强度的变化；随后加入氯胺酮，记录细胞荧光强度的改变。在试验结束前依次加入Triton X-100和EGTA分别记录单个细胞最大荧光强度（Fmax）和最小荧光强度（Fmin），以计算细胞内Ca^2＋的相对强度。结果氯胺酮不改变荷包牡丹碱诱导PCl2细胞内Ca^2＋浓度波动的基线，但抑制细胞内Ca^2＋浓度升高的幅度（P〈0．05），缩短相邻波峰间的时间间隙（P〈0．05）。结论氯胺酮不仅改变荷包牡丹碱诱导PCl2细胞内Ca^2＋浓度升高的幅度，而且改变Ca^2＋浓度波动的周期。     

精子质量参数分析的标准化与质量控制的研究进展

精液分析是评价男性生育能力的最基本测试。最近几年,对精液分析标准化的迫切需求已引起男科学家的广泛重视。本文对精子质量参数———精子密度、活动率和形态学分析的标准化及质量控制进行了综述。精子密度分析的关键是计数池的标准化,因此Cell-VU计数池应该是最佳的选择;精子活动率和精子形态学的分析由于主观性太强,CASA系统可能是其标准化的最终选择。精液质量参数分析的质量控制主要是质量控制材料的选择,以及在男科学实验室实施EQC和IQC项目,而一些监测质量控制的图表和计算方法应被相应地建立。     

基于BIS指数的麻醉给药系统研究设计

麻醉给药研究的关键问题之一是如何保证麻醉药品在人体效应室中的理想浓度。以药代动力学为基础的靶控输注（TCI）是一种可实现的方法,基于BIS指数的实时闭环麻醉给药系统实时控制靶控输注给药可以获得理想的麻醉效果。本文对这一麻醉给药系统的研究提出临床工程设计方案,并加以实现。     

Characterization of Latent Transforming Growth Factor-β From Human Seminal Plasma

PROBLEM : Human seminal plasma is known to exhibit immunosuppressive activity. Transforming growth factor β (TGF-β) has been identified as an immunosuppressive factor in human seminal plasma. Biologically active TGF-β represents a family of 25-kDa homodimeric proteins linked with disulfide bonds. TGF-β associates with high molecular weight proteins noncovalently to form a type of latency that is biologically inactive. Quantitative distribution of active form of TGF-β versus inactive latent form of TGF-β, and mechanism of the TGF-β activation in human seminal plasma remain to be elucidated. PURPOSE : To characterize seminal plasma latent form of TGF-β, including its concentration, and the mechanism underlying the activation of TGF-β. METHOD : Gel filtrations on ACA-34 and Biogel P-60 were used to fractionate seminal plasma. TGF-β was measured by enzyme immunoassay using antibodies specific for TGF-β₁ and TGF-β₂, respectively. Radioreceptor assay with recombinant human [¹²⁵I]-TGF-β₁ was applied to qualitatively identify TGF-β₁. Kinetic experiments with various pH, temperature and time, along with protease inhibitors, were performed to delineate the activation mechanism of latent TGF-β. RESULTS : Human seminal plasma contained both TGF-β₁ and TGF-β₂, predominantly in latent form. The total concentration of TGF-β₁ averaged 238 ng/ml versus an average of 18 ng/ml for TGF-β₂. The in vitro activation or release of TGF-β₁, from latent TGF-β₁ was achieved only at acidic pH of <4.0, and was time and temperature dependent. At pH 3.7 and 37°C, a significant activation of latent TGF-β₁ was achieved after an incubation of only 15 min, reached the maximum at 120 min, and the activated TGF-β₁ remained relatively stable for at least 24 h. The activation was not inhibitable by a series of protease inhibitors examined, alone or in combination (e.g., phenylmethylsulfonyl fluoride, E-64, pepstatin, leupeptin, ethylenediamine tetraacetic acid). Competitive radioreceptor assay established the functional identity of TGF-β₁ in human seminal plasma with recombinant human TGF-β₁. CONCLUSION : Human seminal plasma TGF-β is biologically activated from high molecular weight latent TGF-β by acid pH. The acidic environment of female lower genital tract could represent an in vivo physiological condition for activation of seminal plasma TGF-β that may immunologically protect the integrity of sperm.     

Lower level of serum potassium and higher level of C-reactive protein as an independent risk factor for giant aneurysms in Kawasaki disease

Giant aneurysms are the most serious issue of patients with Kawasaki disease (KD). To clarify risk factors for these giant aneurysms, we conducted a matched case-control study. Among the patients reported in nationwide surveys, 117 patients with giant aneurysms had an unequivocal new diagnosis and presented at the treatment center within 9 d of illness. We obtained clinical information on admission of about 69 patients (case) from the treatment centers. One control was selected for each case, an age- and sex-matched patient without coronary involvement, reported from the same treatment center at about the same time as the case, and we obtained the same clinical information about controls. Fourteen variables were analysed with a conditional logistic regression model: body temperature, hematocrit, hemoglobin, numbers of leukocyte and platelets, concentrations of serum albumin, globulin, total cholesterol, sodium, potassium and chloride, erythrocyte sedimentation rate, C-reactive protein and alanine aminotransferase activity. After adjustment for age, duration of illness before admission and use of intravenous gamma globulin therapy, C-reactive protein [odds ratio (OR) = 1.142, 95% confidence interval (CI) 1.054-1.237], alanine aminotransferase activity (OR = 1.008, 95% CI 1.002-1.014), serum sodium concentration (OR = 0.877, 95% CI 0.770-0.999) and serum potassium concentration (OR = 0.319, 95% CI 0.124-0.822) were significantly related to the risk for giant aneurysms. Further analyses with these four explanatory variables revealed that C-reactive protein (OR = 1.159, 95% CI 1.022-1.315) and serum potassium concentration (OR = 0.222, 95% CI 0.052-0.948) met the significant level. Thus, the values for serum C-reactive protein and potassium are independent risk factors for the development of the giant aneurysms of Kawasaki disease.     

阿霉素不同剂量静脉注射的药动学及其临床意义

采用ＨＰＬＣ法测定１４例肿瘤患者使用不同剂量阿霉素的血药浓度，并计算药代参数。４０ｍｇ／ｍ２和２５ｍｇ／ｍ２两组的血药峰浓度、ＡＵＣ、Ｖｃ差异有显著性。阿霉素的药代动力学存在明显的个体差异，血药峰浓度、Ｖｃ、Ｋ１２与疗效相关。     

Controlled Release of Substituted Benzole and Naphthoic Acids Using Carbopol ® Gels: Measurement of Drug Concentration Profiles and Correlation to Release Rate Kinetics

Purpose. The objective of this study is to correlate drug release mechanism with measured drug concentration profiles in gel layers of Carbopol^® matrices containing mesalamine or benzoic acid. Methods. Release rate experiments with Carbopol^® matrices were performed using a rotating disk apparatus. Matrices were frozen and the gel layer in the matrices was sliced using a microtome in a cryostat. Drug concentration profiles were determined by direct measurement of the concentration of the drug in the gel slices. The pH of the slices was measured using microelectrodes, and water content was measured by Karl Fisher titration. Results. The concentration gradient in mesalamine matrices decreased over time and correlated with square root of time release rate kinetics. The concentration profiles of benzoic acid were unchanged over time and correlated with zero order release rate kinetics. Carbopol gel layers were highly hydrated (93–95% water). Gel layers in matrices with mesalamine had a more alkaline microenvironmental pH. This higher pH resulted in increased growth of the thickness of the gel layer and a reduction drug diffusivity in comparison to benzoic acid matrices. Conclusions. The release rate kinetics of mesalamine and benzoic acid correlated to the measured concentration profiles. The shape of the concentration profiles is determined by the rate of growth of the Carbopol^® gel layer and drug diffusivity.